

**Date: 25th May, 2026**

To,

BSE Limited

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street - Fort,

Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730**Subject: Outcome of the Board Meeting**

Dear Sir / Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, May 25, 2026 has inter-alia, considered, adopted and approved following items of business:

1. The Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2026 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are:
 - a. A copy of the said Financial Results along with the Auditor's Report thereon;
 - b. Declaration of unmodified opinion on the Standalone and Consolidated Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Recommended Final Dividend at 7% i.e. 70 paise per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2025-26; subject to the approval of the Shareholders at the ensuing 39th Annual General Meeting of the Company;

In furtherance to the intimation filed by the Company dated March 26, 2026; the trading window for trading in securities of the Company by insiders closed on April 01, 2026 till the end of 48 hours after the declaration of outcome of this Board Meeting.

3. Increase in the Authorised Share Capital of the Company from Rs. 10 Crores to Rs. 50 Crores subject to the Shareholders' approval in ensuing Annual General Meeting.





4. Issuance of Bonus Shares to the shareholders/ warrant holders of the Company in the ratio of 2:1, i.e. 2 (two) Bonus Equity Shares of face value Rs.10/- each fully paid up; for every 1 (One) existing equity share of face value of Rs.10/- each fully paid up, to the eligible shareholders/ warrant holders of the Company as on the record date, subject to the approval of the Shareholders of the Company.

The Record Date for determining the eligibility of shareholders/warrant holders entitled to receive the Bonus Shares will be intimated in due course.

Further, details as required under Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023, with respect to the Bonus Issue is enclosed as Annexure – 1.

5. Appointment of M/s. Nikhil Maniar & Associates, Chartered Accountants as Internal Auditor of the Company for the Financial Year 2026-2027.

The disclosures pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 and SEBI Circular No. SEBI/HO/CFD/PoD2/ CIR/P/0155 dated November 11, 2024, as Annexure - 2.

6. Appointment of M/s. Joshi Apte & Associates; Practicing Cost Accountants, Mumbai as Cost Auditor of the Company for the Financial Year 2026-2027.

The disclosures pursuant to SEBI Listing Regulations read with SEBI circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 and SEBI Circular No. SEBI/HO/CFD/PoD2/ CIR/P/0155 dated November 11, 2024, as Annexure - 3.

The Board Meeting commenced at 01:00 p.m. and concluded at 02:40 p.m.

Kindly oblige and take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited

Fredun Medhora
Managing Director
DIN: 01745348





Date: 25th May, 2026

To

BSE Limited

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street - Fort,

Mumbai — 400 001

Ref.: BSE Scrip Code - 539730

Sub: Declaration under Regulations 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for Audit Reports on the Standalone and Consolidated Financial Results.

Dear Sir / Madam

Pursuant to Regulations 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Statutory Auditors of the Company has issued an unmodified opinion on the Standalone and Consolidated Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2026.

Request you to kindly take the above on record.

Thanking you,

For Fredun Pharmaceuticals Limited

Fredun Medhora

Managing Director

DIN: 01745348



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



AUDITED STANDALONE FINANCIAL RESULTS FOR THE 4th QUARTER & YEAR ENDED 31.03.2026

Rs. In Lakhs

PARTICULARS	Quarter Ended		Year Ended		
	Audited	Unaudited	Audited	Audited	Audited
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
1 Income from Operations					
Net Sales /IncomeFrom Operation (Net of GST)	21,041.20	15,992.63	16,543.76	63,332.65	45,170.62
2 Other Operating Income	264.00	99.70	196.96	579.52	456.20
3 Total income from operations (net)	21,305.20	16,092.33	16,740.72	63,912.17	45,626.82
4 Expenses					
a) Cost of Material Consumed	17,354.16	11,763.43	12,432.81	48,075.96	32,188.90
b) Cost of Material Consumed for R & D	186.34	127.64	68.18	507.77	209.34
c) Other R & D Expenses	-	-	-	-	-
d) Changes in inventories of finished goods, work-in-progress and stock in trade	(2,209.03)	(735.43)	(123.36)	(3,169.31)	605.00
e) Manufacturing & Service Cost	464.66	372.21	458.97	1,566.91	1,755.54
f) Finance Costs	1,448.51	1,054.95	814.74	3,929.76	2,237.66
g) Employess benefits expenses	886.45	814.62	969.79	3,294.34	2,223.12
h) Depreciation and amortisation expenses	311.27	178.40	124.95	791.38	444.91
i) Other Expenses	1,709.52	1,116.26	1,190.47	4,157.16	3,135.27
Total expenses	20,151.88	14,692.08	15,936.55	59,153.97	42,799.74
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	1,153.32	1,400.25	804.17	4,758.20	2,827.08
6 Exceptional items / Prior Period Item	-	-	-	-	-
7 Profit/(Loss) from ordinary activities before tax (5-6)	1,153.32	1,400.25	804.17	4,758.20	2,827.08
8 Tax Expenses	46.81	352.44	96.99	1,437.51	746.32
9 Profit/(Loss) from continuing operations	1,106.51	1,047.81	707.18	3,320.69	2,080.76
10 Profit/(Loss) from discontinued operations	-	-	-	-	-
11 Tax Expense of discontinued operations	-	-	-	-	-
12 Profit/(Loss) from discontinued operations after tax	-	-	-	-	-
13 Profit/ (Loss) for the period	1,106.51	1,047.81	707.18	3,320.69	2,080.76
14 Other comprehensive Income					
A (i) Items that will not be re-classified to profit/ loss	-	-	-	-	-
(ii) Income tax relating to items that will not be re-classified to profit/ loss	-	-	-	-	-
B (i) Re measurement of post - employment benefit obligations	16.55	-	(34.35)	16.55	(34.35)
C (ii) Items that will be re-classified to profit / loss	-	-	-	-	-
(iii) Income tax relating to items that will be re-classified to profit/ loss	-	-	-	-	-
Total Comprehensive Income for the year	1,123.06	1,047.81	672.83	3,337.24	2,046.41
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	547.27	536.60	472.17	547.27	472.17
16 Reserves excluding Revaluation Reserves	-	-	-	-	13,667.93
17 Earning per Share (EPS) (before & after extra ordinary items)					
Basic Earning Per Share (Rs.)	20.22	19.53	14.98	68.01	44.83
Diluted Earning Per Share (Rs.)	18.70	17.71	-	62.33	44.37



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

AUDITED STANDALONE FINANCIAL RESULTS FOR THE 4th QUARTER & YEAR ENDED 31.03.2026

Rs. In Lakhs

PARTICULARS	Quarter Ended			Year Ended	
	Audited	Unaudited	Audited	Audited	Audited
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
1) Public Shareholding					
Number of shares	30,55,637	30,55,637	24,11,277	30,55,637	24,11,277
Percentage of shareholding	55.83%	56.94%	51.07%	55.83%	51.07%
2) Promoters and promotor group shareholding					
a) Pledged/Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Promoter Group)	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-
b) Non-encumbered					
- Number of shares	24,17,053	23,10,385	23,10,385	24,17,053	23,10,385
- Percentage of shares (as a % of total shareholding of Promoters and Promoter Group)	44.17%	43.06%	48.93%	44.17%	48.93%
- Percentage of shares (as a % of total share capital of the Company)	100.00%	100.00%	100.00%	100.00%	100.00%

Notes

- The above audited standalone financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 25, 2026. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
 - The above audited standalone financial results for the quarter ended March 31, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued audit reports with unmodified opinion on the audited standalone financial results
 - As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
 - The Board of Directors has recommended final dividend of Re. 0.70 paise per share. The payment is subject to approval of shareholders in the ensuing Annual General Meeting of the Company
- Issuance of Bonus Shares to the shareholders/ warrant holders of the Company in the ratio of 2:1, i.e. 2 (two) Bonus Equity Shares of face value ₹10/- each fully paid up; for every 1 (One) existing equity share of face value of ₹10/- each fully paid up, to the eligible shareholders/ warrant holders of the Company as on the record date, subject to the approval of the Shareholders of the Company.
- The figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the year ended March 31 and the published year to date unaudited figures for the nine months ended ended December 31 of the respective financial year.
 - The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current period.

PLACE: MUMBAI

DATE : 25th May, 2026

FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO
FREDUN N. MEDHORA
DIN : 01745348



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

AUDITED STATEMENT OF ASSETS AND LIABILITIES FOR THE ENDED 31.03.2026			
		Amount in Lakhs	
Particulars	As at 31.03.2026	As at 31.03.2025	
A ASSETS			
1) Non-current assets			
(a) Property, Plant and equipment	11,760.54	5,213.97	
(b) Capital work in Progress	-	-	
(c) Financial Assets	-	-	
1) Loans	-	-	
2) Other financial assets	1,578.98	833.28	
3) Other Intangible Assets	62.94	42.72	
(d) Non - Current Investment	201.73	151.33	
(e) Other non current assets	785.30	198.99	
Sub-total - Non-current assets	14,389.49	6,440.29	
2) Current assets			
(a) Inventories	26,980.45	23,988.89	
(b) Financial assets	-	-	
(1) Investments	-	-	
(2) Trade and other receivable	9,268.52	17,712.08	
(3) Cash and cash equivalents	6,490.41	22.97	
(4) Bank Balance Other Than 3 above	4.91	5.03	
(5) Loans	99.28	46.99	
(6) Other financial assets	5,455.49	120.27	
(c) Other current Assets	1,525.34	328.64	
Sub-total - Current assets	49,824.40	42,224.87	
TOTAL - ASSETS	64,213.89	48,665.16	
B EQUITY & LIABILITIES			
1 Shareholders' Funds			
a) Equity Share Capital	547.27	472.17	
b) Other Equity	27,323.90	13,667.93	
Sub-total - Shareholders' Funds	27,871.17	14,140.10	
2 Share application money pending allotment	-	-	
3 Non Current Liabilities			
a) Borrowings	5,631.02	961.30	
b) Provisions	425.55	383.29	
c) Deferred Tax Liabilities (Net)	654.80	448.40	
Sub-total - Non Current Liabilities	6,711.37	1,792.99	
4 Current Liabilities			
a) Financial Liabilities			
1) Borrowings	16,572.03	15,679.36	
2) Trade Payables	8,746.68	14,475.80	
3) Other Financial Liabilities	4.84	5.10	
b) Other Current Liabilities	3,353.72	1,860.23	
c) Current tax liabilities (Net)	954.07	711.58	
Sub-total - Current Liabilities	29,631.34	32,732.07	
TOTAL EQUITY AND LIABILITIES	64,213.89	48,665.16	

PLACE : MUMBAI
DATE : 25th May, 2026

FOR FREDUN PHARMACEUTICALS LIMITED



MR. FREDUN NARIMAN MEDHORA
DIN : 01745348
MANAGING DIRECTOR & CFO



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2026

	<u>F.Y. 2025-2026</u>	<u>F.Y. 2024-2025</u>
A) CASH FLOW FROM OPERATING ACTIVITIES:		
NET PROFIT AFTER TAXATION	3,320.69	2,080.76
<u>ADJUSTMENTS FOR :</u>		
DEPRECIATION	791.38	444.91
INTEREST PAID	3,748.78	2,237.66
INTEREST RECEIVED	42.31	11.04
CREDITORS WRITTEN BACK	0.00	6.64
	<u>4,582.47</u>	<u>2,700.25</u>
	7,903.16	4,781.01
<u>ADJUSTMENT TO OPERATING PROFIT</u>		
PRIOR PERIOD ADJUSTMENTS	-	-
DEFERRED TAX LIABILITY	206.40	34.75
ADJUSTMENT FOR PROPOSED DIVIDEND TAX	-	-
ADJUSTMENT FOR TAX PROVISION	<u>0.00</u>	<u>711.58</u>
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	8,109.56	5,527.33
<u>EFFECTS OF CHANGES IN WORKING CAPITAL ITEMS</u>		
<u>INCREASE / DECREASE IN :-</u>		
INVENTORY	-2,991.56	-6,489.09
TRADE RECEIVABLES	8,443.56	-11,227.20
LOANS & ADVANCES	-52.29	-22.41
OTHER CURRENT ASSETS	-1,196.70	826.55
OTHER FINANCIAL ASSETS	-5,335.22	219.41
OTHER FINANCIAL ASSETS	-745.70	-183.50
TRADE PAYABLES	-5,729.12	8,181.10
OTHER CURRENT LIABILITIES	1,493.49	1,300.69
OTHER NON CURRENT ASSETS	-586.31	-385.27
OTHER NON CURRENT INVESTMENTS	-50.40	-151.33
OTHER FINANCIAL LIABILITIES	-0.26	1.26
SHORT TERM PROVISION	-	-
PROVISION FOR TAX	242.49	158.08
RESERVES & SURPLUS	10,335.29	-1,244.26
SHARE PREMIUM (RESERVES & SURPLUS)	<u>3,827.27</u>	<u>-9,015.97</u>
	11,936.83	-3,488.64

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

INCREASE / DECREASE IN :-

LONG TERM LOANS & ADVANCES

LONG TERM PROVISIONS

42.26

146.71

42.26

146.71

NET CASH FLOW FROM OPERATING ACTIVITIES

11,979.09

-3,341.93

EFFECTS OF CHANGES IN NON CURRENT ITEMS

OTHER NON CURRENT ASSETS

NET ADJUSTED CASH FLOW FROM OPERATING ACTIVITIES

11,979.09

-3,341.93

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2026

B) CASH FLOW FROM INVESTING ACTIVITIES

PURCHASE OF FIXED ASSETS

-7,358.17

-599.43

SALE OF FIXED ASSETS

-

-

CAPITAL WORK IN PROGRESS

-

-

-7,358.17

-599.43

4,620.92

-3,941.36

C) CASH FLOW FROM FINANCING ACTIVITIES

INCREASE / DECREASE IN ISSUE OF SHARE CAPITAL

75.10

-

INCREASE / DECREASE IN LONG TERM BORROWINGS

4,669.72

-318.51

INCREASE / DECREASE IN SHORT TERM BORROWINGS

892.67

6,408.18

INTEREST RECEIVED

-42.31

-11.04

INTEREST PAID

-3,748.78

-2,237.66

CREDITORS WRITTEN BACK

-

-6.64

1,846.40

3,834.34

NET INCREASE / DECREASE IN CASH

6,467.32

-107.02

OPENING CASH & BANK BALANCE

28.00

135.02

CLOSING CASH & BANK BALANCE

6,495.32

28.00

Place - Mumbai

Date :- 25-May-2026



For Fredun Pharmaceuticals Limited

Mr. Fredun N. Medhpra
Managing Director & CFO
DIN : 01745348

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089

Contact No: 9867351724 Email – rakesh.nisar1@gmail.com

Independent Auditor's Report

To
The Board of Directors of
Fredun Pharmaceuticals Limited,

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of Fredun Pharmaceutical Limited (the "Company") for the quarter ended March 31, 2026 and for the year ended March 31, 2026 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

I. is presented in accordance with the requirements of the Listing Regulations in this regard;

And

II. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income/loss and other financial information of the Company for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended (the "Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



R.H.Nisar & Co.
Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089

Contact No: 9867351724 Email – rakesh.nisar1@gmail.com

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income/loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a



R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089

Contact No: 9867351724 Email – rakesh.nisar1@gmail.com

material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 14 3 (3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089

Contact No: 9867351724 Email – rakesh.nisar1@gmail.com

- There has been a delay in transfer of unclaimed dividend amounts and the corresponding equity shares to the Investor Education and Protection Fund ("IEPF") in accordance with the provisions of Sections 124(5) and 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended.

The Company was required to transfer to the IEPF the unclaimed dividend pertaining to the financial year 2015-16, together with the corresponding equity shares in respect of which dividend had remained unclaimed for seven consecutive years, during the financial year 2023-24. Further, the Company was required to transfer the unclaimed dividend pertaining to the financial year 2016-17 and the corresponding equity shares during the financial year 2024-25, and the unclaimed dividend pertaining to the financial year 2017-18 and the corresponding equity shares during the financial year 2025-26.

However, as at 31 March 2026, the aforesaid transfers had not been completed within the timelines prescribed under the Act and the Rules made thereunder.

Management has represented that it is in the process of undertaking the necessary actions for transfer of the applicable unclaimed dividend amounts and corresponding equity shares to the IEPF and completion of related statutory filings.

- The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For R H NISAR & CO
CHARTERED ACCOUNTANTS
Firm Registration No – 120895W



RAKESH NISAR
(PROPRIETOR)
Membership No.: 103659

Place: Mumbai
Date: 25th May, 2026
UDIN - 26103659AYTTXA7821



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE 4th QUARTER & YEAR ENDED 31.03.2026

Rs. In Lakhs

PARTICULARS	Quarter Ended			Year Ended	
	Audited	Unaudited	Audited	Audited	Audited
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
1 Income from Operations					
Net Sales /IncomeFrom Operation (Net of GST)	21,041.20	15,992.63	16,543.78	63,332.65	45,170.65
2 Other Operating Income	264.31	99.70	196.96	579.84	456.20
3 Total income from operatoins (net)	21,305.51	16,092.33	16,740.74	63,912.49	45,626.85
4 Expenses					
a) Cost of Material Consumed	17,354.15	11,763.43	12,432.81	48075.96	32,188.89
b) Cost of Material Consumed for R & D	186.33	127.64	68.18	507.77	209.34
c) Other R & D Expenses	-	-	-	0.00	-
d) Changes in inventories of finished goods, work-in-progress and stock in trade	(2,209.02)	(735.43)	(123.36)	(3169.31)	605.00
e) Manufacturing & Service Cost	464.66	372.21	458.97	1566.91	1,755.54
f) Finance Costs	1,448.51	1,054.95	814.74	3929.76	2,237.66
g) Employess benefits expenses	886.45	814.62	969.79	3294.34	2,223.12
h) Depreciation and amortisation expenses	315.05	178.40	183.98	824.67	503.95
i) Other Expenses	1,734.57	1,116.27	1,209.19	4182.77	3,153.99
Total expenses	20,180.70	14,692.09	16,014.30	59212.89	42,877.50
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	1,124.81	1,400.24	726.44	4699.60	2,749.35
6 Exceptional items / Prior Period Item	-	-	-	0.00	-
7 Profit/(Loss) from ordinary activities before tax (5-6)	1,124.81	1,400.24	726.44	4699.60	2,749.35
8 Tax Expenses	46.81	352.44	126.09	1437.51	775.42
9 Profit/(Loss) from continuing operations	1,078.00	1,047.80	600.35	3262.09	1,973.93
10 Profit/(Loss) from discontinued operations	-	-	-	0.00	-
11 Tax Expense of discontinued operations	-	-	-	0.00	-
12 Profit/(Loss) from discontinued operations after tax	-	-	-	0.00	-
13 Profit/ (Loss) for the period	1,078.00	1,047.80	600.35	3262.09	1,973.93
14 Other comprehensive Income					
A (i) Items that will not be re-classified to profit/ loss	-	-	-	0.00	-
(ii) Income tax relating to items that will not be re-classified to profit/ loss	-	-	-	0.00	-
B (i) Re measurement of post - employment benefit obligations	16.55	-	(34.35)	16.95	(34.35)
C (ii) Items that will be re-classified to profit / loss	-	-	-	0.00	-
(iii) Income tax relating to items that will be re-classified to profit/ loss	-	-	-	0.00	-
Total Comprehensive Income for the year	1,094.55	1,047.80	566.00	3279.00	1,939.58
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	547.27	536.60	472.17	547.27	472.17
16 Reserves excluding Revaluation Reserves	-	-	-	-	-
17 Earning per Share (EPS) (before & after extra ordinary items)					
Basic Per Sahre (Rs.)	19.70	19.53	12.71	66.81	41.79
Diluted Earning Per Share (Rs.)	18.22	17.71	-	61.23	42.53



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE 4th QUARTER & YEAR ENDED 31.03.2026

PARTICULARS	Rs. In Lakhs				
	Quarter Ended			Year Ended	
	Audited 31.03.2026	Unaudited 31.12.2025	Audited 31.03.2025	Audited 31.03.2026	Audited 31.03.2025
1) Public Shareholding					
Number of shares	30,55,637	30,55,637	24,11,277	30,55,637	24,11,277
Percentage of shareholding	55.83%	56.94%	51.07%	55.83%	51.07%
2) Promoters and promotor group shareholding					
a) Pledged/Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Promoter Group)	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-
b) Non-encumbered					
- Number of shares	24,17,053	23,10,385	23,10,385	24,17,053	23,10,385
- Percentage of shares (as a % of total shareholding of Promoters and Promoter Group)	44.17	43.06	48.93	44.17	48.93
- Percentage of shares (as a % of total share capital of the Company)	100.00%	100.00%	100.00%	100.00%	100.00%

Notes

- 1 The above audited consolidated financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 25, 2026. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above audited consolidated financial results for the quarter ended March 31, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued audit reports with unmodified opinion on the audited standalone financial results
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment

PLACE: MUMBAI

DATE : 25th May, 2026

FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO
FREDUN N. MEDHORA
DIN : 01745348



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



AUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES FOR THE YEAR ENDED 31.03.2026

		Amount in Lakhs	
	Particulars	As at 31.03.2026	As at 31.03.2025
A	ASSETS		
	1) Non-current assets		
	(a) Property, Plant and equipment	11,762.87	5,248.93
	(b) Other Intangible Assets	63.20	42.72
	(c) Financial Assets		
	1) Investments	200.73	150.33
	2) Other financial assets	1,578.98	379.69
	(d) Other non current assets	785.30	198.99
	Sub-total - Non-current assets	14,391.08	6,020.66
	2) Current assets		
	(a) Inventories	26,980.45	23,988.89
	(b) Financial assets		
	(1) Trade and other receivable	9,268.52	17,712.08
	(2) Cash and cash equivalents	6,492.66	63.69
	(3) Bank Balance Other Than 3 above	5.40	458.63
	(4) Loans	87.05	46.99
	(5) Other financial assets	5,455.49	120.29
	(c) Other current Assets	1,527.59	329.91
	Sub-total - Current assets	49,817.16	42,720.48
	TOTAL - ASSETS	64,208.24	48,741.14
B	EQUITY & LIABILITIES		
	1 Shareholders' Funds		
	a) Equity Share Capital	547.27	472.17
	b) Other Equity	27,263.50	13,666.10
	Sub-total - Shareholders' Funds	27,810.77	14,138.27
	2 Share application money pending allotment	-	-
	3 Non Current Liabilities		
	a) Borrowings	5,631.03	961.30
	b) Provisions	425.55	383.29
	c) Other non- Current liabilities	0.00	0.02
	d) Deferred Tax Liabilities (Net)	654.80	448.40
	Sub-total - Non Current Liabilities	6,711.38	1,793.01
	4 Current Liabilities		
	a) Financial Liabilities		
	1) Borrowings	16,609.03	15,753.36
	2) Trade Payables	8,758.27	14,476.58
	3) Other Financial Liabilities	4.85	5.10
	b) Other Current Liabilities	3,359.88	1,863.23
	c) Short term provisions	0.00	0.00
	d) Current tax liabilities (Net)	954.06	711.59
	Sub-total - Current Liabilities	29,686.09	32,809.86
	TOTAL EQUITY AND LIABILITIES	64,208.24	48,741.14

PLACE : MUMBAI
DATE : 25th May, 2026

FOR FREDUN PHARMACEUTICALS LIMITED

MR. FREDUN NARIMAN MEDHORA
DIN : 01745348
MANAGING DIRECTOR & CFO



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



Consolidated Cash Flow for the year ended 31 March, 2026

	F.Y. 2025-2026		F.Y. 2024-2025
A) CASH FLOW FROM OPERATING ACTIVITIES:			
NET PROFIT AFTER TAXATION	0.00	3,262.09	2,003.03
<u>ADJUSTMENTS FOR:</u>	0.00	0.00	
DEPRECIATION	824.67	0.00	503.94
INTEREST PAID	3,748.79	0.00	2,237.66
INTEREST RECEIVED	42.31	0.00	11.04
CREDITORS WRITTEN BACK	-		6.64
		4,615.77	2,759.28
		7,877.86	4,762.31
<u>ADJUSTMENT TO OPERATING PROFIT</u>			
PRIOR PERIOD ADJUSTMENTS		-	-
DEFERRED TAX LIABILITY		206.40	34.75
ADJUSTMENT FOR PROPOSED DIVIDEND TAX		-	-
ADJUSTMENT FOR TAX PROVISION		-	711.58
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES		8,084.26	5,508.63
<u>EFFECTS OF CHANGES IN WORKING CAPITAL ITEMS</u>			
<u>INCREASE / DECREASE IN :-</u>			
INVENTORY	-2,991.56		-6,489.09
INVESTMENTS	-		-
TRADE RECEIVABLES	8,443.56		-11,227.20
LOANS & ADVANCES	-40.06		-22.41
OTHER CURRENT ASSETS	-1,197.68		826.55
OTHER FINANCIAL ASSETS	-5,335.21		219.41
OTHER FINANCIAL ASSETS	-1,199.29		-183.50
TRADE PAYABLES	-5,718.32		8,184.10
OTHER CURRENT LIABILITIES	1,496.65		1,300.69
OTHER NON CURRENT ASSETS	-586.31		-12.75
OTHER NON CURRENT INVESTMENTS	-50.40		-70.26
OTHER FINANCIAL LIABILITIES	-0.26		1.26
SHORT TERM PROVISION	-		-
PROVISION FOR TAX	242.50		158.08
RESERVES & SURPLUS	10,335.31		-1,246.51
SHARE PREMIUM (RESERVES & SURPLUS)		3,398.94	-8,561.63
		11,483.20	-3,052.99
<u>INCREASE / DECREASE IN :-</u>			
LONG TERM LOANS & ADVANCES			-
LONG TERM PROVISIONS	42.26		146.71
		42.26	146.71
NET CASH FLOW FROM OPERATING ACTIVITIES		11,525.45	-2,906.29
EFFECTS OF CHANGES IN NON CURRENT ITEMS			-
OTHER NON CURRENT ASSETS		-	-
NET ADJUSTED CASH FLOW FROM OPERATING ACTIVITIES		11,525.45	-2,906.29



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

B) CASH FLOW FROM INVESTING ACTIVITIES

PURCHASE OF FIXED ASSETS	-7,359.08	-610.62
SALE OF FIXED ASSETS		11.19
Purchase of Investment in Associates/Subsidiary	-	-35.99
CAPITAL WORK IN PROGRESS	-	-
	-7,359.08	-635.42
	4,166.37	-3,541.70

C) CASH FLOW FROM FINANCING ACTIVITIES

INCREASE / DECREASE IN ISSUE OF SHARE CAPITAL	75.10	3.25
INCREASE / DECREASE IN LONG TERM BORROWINGS	4,669.72	-244.51
INCREASE / DECREASE IN SHORT TERM BORROWINGS	855.67	6,408.18
INTEREST RECEIVED	-42.31	-11.04
INTEREST PAID	-3,748.79	-2,237.66
CREDITORS WRITTEN BACK	-	-6.64
	1,809.40	3,911.59
NET INCREASE / DECREASE IN CASH	5,975.77	369.89
OPENING CASH & BANK BALANCE	522.31	152.42
CLOSING CASH & BANK BALANCE	6,498.07	522.31

Place - Mumbai

Date :- 25th May-2026

For Fredun Pharmaceuticals Limited

Mr. Fredun N. Medhore
Managing Director & CFO
DIN : 01745348



Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

R.H.Nisar & Co.

Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063

Tel no: 2686 9939, 2686 9940

Independent Auditor's Report

To
The Board of Directors of
Fredun Pharmaceuticals Limited,

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying annual Consolidated Financial Results of **FREDUN PHARMACEUTICALS LIMITED** (hereinafter referred to as the "the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as the "Group"), for the year ended March 31, 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid, Consolidated Financial Results:

- i) Include the financials results of following entites,

Incorporated in India

- a. Fredun Retail Private Limited
- b. One Pet Stop Private Limited
- c. Wagr Retail Private Limited

- ii) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations, in this regard; and
- iii) give a true and fair view in conformity with the recognition and measurement principles of the applicable Indian Accounting Standards (Ind AS), and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2026.



R.H.Nisar & Co.

Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063

Tel no: 2686 9939, 2686 9940

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI & e of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated Financial Results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.



R.H.Nisar & Co.

Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063

Tel no: 2686 9939, 2686 9940

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.



R.H.Nisar & Co.

Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063

Tel no: 2686 9939, 2686 9940

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial results of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

- There has been a delay in transfer of unclaimed dividend amounts and the corresponding equity shares to the Investor Education and Protection Fund ("IEPF") in accordance with the provisions of Sections 124(5) and 124(6) of the Companies Act, 2013 read with the applicable rules thereunder.

As represented by the management, the aforesaid matter pertains to the Holding Company. The Holding Company was required to transfer to the IEPF the unclaimed dividend pertaining to the financial year 2015-16, together with the corresponding equity shares in respect of which dividend had remained unclaimed for seven consecutive years, during the financial year 2023-24. Further, the Holding Company was required to transfer the unclaimed dividend pertaining to the financial year 2016-17 and the corresponding equity shares during the financial year 2024-25, and the unclaimed dividend pertaining to the financial year 2017-18 and the corresponding equity shares during the financial year 2025-26.



R.H.Nisar & Co.

Chartered Accountant

4, Vrindavan Building, Aarey Road, Goregaon (E), Mumbai – 400 063

Tel no: 2686 9939, 2686 9940

However, as at 31 March 2026, such transfers had not been completed within the timelines prescribed under the Act and the applicable rules thereunder.

Management has represented that necessary actions are being undertaken for transfer of the applicable unclaimed dividend amounts and corresponding equity shares to the IEPF and completion of related statutory filings.

Our opinion on these Consolidated Financial Results is not modified in respect of the above matter

For R H NISAR & CO
CHARTERED ACCOUNTANTS
Firm Registration No – 120895W



RAKESH NISAR
(PROPRIETOR)
Membership No.: 103659

Place: Mumbai
Date: 25th May, 2026
UDIN -26103659GYLNAU8081



**Annexure - 1**

Details as required under Regulation 30 of SEBI (LODR) Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023.

Sr. No.	Particulars	Description
1	Types of Securities proposed to be issued	Equity Shares of face value Rs. 10/- per Share.
2	Type of issuance	Bonus Issue of Equity Shares
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued	1,10,25,380 equity shares of face value Rs.10/- each. The actual number of bonus shares to be issued will be determined based on the fully paid-up equity shares as on the record date.
4	Whether bonus is out of free reserves created out of profits or share premium account	The bonus shares will be issued out of securities premium account received in cash and / or general reserve and / or retained earnings available as at March 31, 2026.
5	Bonus ratio	2:1 i.e. 2 (Two) new fully paid-up equity share of Rs.10/- (Rupees Ten Only) each for every 1 (one) existing fully paid-up equity share of Rs.10/- (Rupees Ten Only) each, to the eligible equity shareholders/warrant holders of the Company as on record date.
6	Details of Share Capital - pre and post bonus issue Pre-bonus issue paid-	Pre- Bonus Issue paid-up Share Capital as on date: 55,12,690 equity shares of Rs. 10/- each aggregating Rs.5,51,26,900.





		Post-bonus issue paid-up Share Capital: 1,65,38,070 equity shares of Rs. 10/- each aggregating Rs. 16,53,80,700. The actual number of bonus shares to be issued will be determined based on the fully paid-up equity shares as on the record date.
7	Free Reserves and / or share premium required for implementing the bonus issue	Rs. 11,02,53,800 (based on estimated number of bonus shares as per Point (6) above). The actual paid-up share capital will be determined based on the paid-up share capital as on the record date.
8	Free reserves and / or share premium available for capitalization and the date as on which such balance is available	As on March 31, 2026 (as per latest audited balance sheet): a. Securities Premium - Rs. 162.39 crore; b. General Reserve (including Retained Earnings) - Rs. 96.95 crore;
9	Whether the aforesaid figures are audited	Yes, the figures at Point (8) above are audited.
10	Estimated date by which such bonus shares would be credited/dispatched;	On or before July 24, 2026.



**Annexure - 2****A. Details relating to the appointment of Internal Auditor:**

Particulars	Details
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment: to comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Date of appointment & term of appointment	Appointment in the Board Meeting held on May 25, 2026, for the FY 2026-27.
Brief profile	Name of the Auditor: Nikhil Maniar & Associates., Chartered Accountants. Office Address: Amar Kunj Building, Office no: 01, Plot No - 1/2B, Besant Street, Santacruz (W), Mumbai- 400054. E-mail: canikhilmaniar@yahoo.co.in canikhilmaniar18@gmail.com Field of Experience: Audit & Assurance, Taxation, etc. About the Auditor: Nikhil Maniar & Associates., (Chartered Accountants) offers a comprehensive set of services including Audit and Tax Advisory, Compliance, Assurance Services, GST & Compliance, etc.
Disclosure of relationships between directors	Not Applicable.



**Annexure - 3****B. Details relating to the appointment of Cost Auditor:**

Particulars	Details
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment: to comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Date of appointment & term of appointment	Appointment in the Board Meeting held on May 25, 2026, for the FY 2026-27.
Brief profile	M/s. Joshi Apte and Associates is a leading Cost and Management Accounting firm headquartered in Thane, Mumbai, specializing in cost audits under Section 148 of the Companies Act, 2013. With a team of experienced professionals, the firm offers a comprehensive range of services, including GST consulting, ERP implementation, stock audits, and internal audits, catering to various industries such as pharmaceuticals, construction, and telecommunications.
Disclosure of relationships between directors	Not Applicable.

